Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 5
2019 3
2020 2
2021 8
2022 5
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma.
Inai K, Kitagawa K, Murakami M, Iwasaki T. Inai K, et al. J Vet Med Sci. 2022 Jan 7;84(1):36-39. doi: 10.1292/jvms.21-0346. Epub 2021 Dec 6. J Vet Med Sci. 2022. PMID: 34866072 Free PMC article.
Despite long-term corticosteroid therapy, the patient's physiological (pruritus) and dermatological signs (alopecia, erythema, erosion, and ulceration with crust) progressed and showed no evidence of improvement. To address the worsening condition of pruritus, lokivetmab w …
Despite long-term corticosteroid therapy, the patient's physiological (pruritus) and dermatological signs (alopecia, erythema, erosion, and …
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs.
Krautmann M, Walters RR, King VL, Esch K, Mahabir SP, Gonzales A, Dominowski PJ, Sly L, Mwangi D, Foss DL, Rai S, Messamore JE, Gagnon G, Schoell A, Dunham SA, Martinon OM. Krautmann M, et al. Vet Immunol Immunopathol. 2023 Apr;258:110574. doi: 10.1016/j.vetimm.2023.110574. Epub 2023 Feb 21. Vet Immunol Immunopathol. 2023. PMID: 36842258 Free article.
Lokivetmab (Cytopoint, Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokivetmab is approved for use in dogs for the treatment of atopic dermatitis (AD) and allergic dermatitis. ...
Lokivetmab (Cytopoint, Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokive
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis.
Meichner K, Kiupel M, Kasantikul T, Rakich P, Banovic F. Meichner K, et al. Vet Dermatol. 2019 Feb;30(1):73-e22. doi: 10.1111/vde.12702. Epub 2018 Nov 26. Vet Dermatol. 2019. PMID: 30479052
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin …
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's …
Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs.
Bruet V, Mosca M, Briand A, Bourdeau P, Pin D, Cochet-Faivre N, Cadiergues MC. Bruet V, et al. Vet Sci. 2022 Mar 22;9(4):149. doi: 10.3390/vetsci9040149. Vet Sci. 2022. PMID: 35448647 Free PMC article. Review.
The molecules reviewed here are systemic and topical glucocorticoids, antihistamines, ciclosporin, oclacitinib and lokivetmab. A level of evidence (1, 2 or 3) has been established according to a detailed algorithm for each individual study in the literature published betwe …
The molecules reviewed here are systemic and topical glucocorticoids, antihistamines, ciclosporin, oclacitinib and lokivetmab. A leve …
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ, Norris LR, Mahabir S, Walters RR, Martinon O, Dunham SA, Gonzales AJ. Fleck TJ, et al. Vet Dermatol. 2021 Dec;32(6):681-e182. doi: 10.1111/vde.12943. Epub 2021 Apr 8. Vet Dermatol. 2021. PMID: 33830571 Free PMC article.
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetmab. Laboratory beagle dogs were given either placebo, 0.125, 0.5 or 2.0 mg/kg lokivetmab, subcutaneously. IL-31 then was administe …
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetma
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab.
Tamamoto-Mochizuki C, Crawford N, Eder JM, Gonzales AJ, Olivry T. Tamamoto-Mochizuki C, et al. Vet Dermatol. 2023 Aug;34(4):327-338. doi: 10.1111/vde.13159. Epub 2023 Apr 2. Vet Dermatol. 2023. PMID: 37006124
BACKGROUND: The caninised monoclonal antibody lokivetmab (LKV), directed at interleukin (IL)-31, is very effective at controlling pruritus in most dogs with atopic dermatitis (AD). ...
BACKGROUND: The caninised monoclonal antibody lokivetmab (LKV), directed at interleukin (IL)-31, is very effective at controlling pru …
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
Calesso JR, Marques VS, de Carvalho OV, Costa-Val AP. Calesso JR, et al. Pol J Vet Sci. 2023 Jun;26(2):231-238. doi: 10.24425/pjvs.2023.145027. Pol J Vet Sci. 2023. PMID: 37389418
To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inhibitor of this key cytokine in pruritus. ...Ten client-owned dogs diagnosed with AD received two injections of lokivetmab four weeks …
To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inh …
Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E, Videmont E. Bensignor E, et al. Vet Dermatol. 2022 Feb;33(1):68-e22. doi: 10.1111/vde.13004. Epub 2021 Aug 19. Vet Dermatol. 2022. PMID: 34414621
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. ...A longer-lasting remission was noted in Group B compared to Group A; dogs receiving the combined treatment showed an extended time to flare compared to dogs treated with lokivetmab
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. ...A longer-lasting remission was noted in Group …
Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
van Amersfort K, Vernooij JCM, van der Lee A. van Amersfort K, et al. Vet Dermatol. 2023 Oct;34(5):373-384. doi: 10.1111/vde.13165. Epub 2023 Apr 26. Vet Dermatol. 2023. PMID: 37186491
OBJECTIVE: To compare clinical efficacy of six monthly ILIT injections combined with three monthly injections of lokivetmab (LVM) with monthly LVM monotherapy at Day (D)168. To monitor dogs treated with ILIT for an additional six months of subcutaneous immunotherapy (SCIT) …
OBJECTIVE: To compare clinical efficacy of six monthly ILIT injections combined with three monthly injections of lokivetmab (LVM) wit …
29 results